Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Merrill Lynch Ups Celgene To Buy from Neutral

Merrill Lynch upgraded Celgene (CELG) to buy from neutral, citing the stock's valuation.

Analyst Thomas McGahren said he's been positive on Celgene for a while now, but it was too rich. He's upping his recommendation to a buy rating with a $65 target as the stock has drifted downward recently to a good entry point; the stock was off 20% following Oct. 3 news of a drug approval delay. He says the company is a profitable oncology-focused biotech offering a potential blockbuster franchise in Revlimid, Thalomid. He sees 54 cents 2005 earnings per share on revenue of $437 million, and $1.06 2006 earnings per share on revenue of $642 million. He says the $65 target is based on a p-e of 49 times 2007 earnings per share estimate of $1.60, discounted back one year at 20%.

blog comments powered by Disqus